Niclosamide Exhibits Potent Anticancer Activity and Synergizes with Sorafenib in Human Renal Cell Cancer Cells
2018
Xinyi Yu | Feng Liu | Liyi Zeng | Fang He | Ruyi Zhang | Shujuan Yan | Zongyue Zeng | Yi Shu | Chen Zhao | Xingye Wu | Jiayan Lei | Wenwen Zhang | Chao Yang | Ke Wu | Ying Wu | Liping An | Shifeng Huang | Xiaojuan Ji | Cheng Gong | Chengfu Yuan | Linghuan Zhang | Yixiao Feng | Bo Huang | Wei Liu | Bo Zhang | Zhengyu Dai | Xi Wang | Bo Liu | Rex C. Haydon | Hue H. Luu | Hua Gan | Tong-Chuan He | Liqun Chen
Background/Aims: As the most lethal urological cancers, renal cell carcinoma (RCC) comprises a heterogeneous group of cancer with diverse genetic and molecular alterations. There is an unmet clinical need to develop efficacious therapeutics for advanced, metastatic and/or relapsed RCC. Here, we investigate whether anthelmintic drug Niclosamide exhibits anticancer activity and synergizes with targeted therapy Sorafenib in suppressing RCC cell proliferation. Methods: Cell proliferation and migration were assessed by Crystal violet staining, WST-1 assay, cell wounding and cell cycle analysis. Gene expression was assessed by qPCR. In vivo anticancer activity was assessed in xenograft tumor model. Results: We find that Niclosamide effectively inhibits cell proliferation, cell migration and cell cycle progression, and induces apoptosis in human renal cancer cells. Mechanistically, Niclosamide inhibits the expression of C-MYC and E2F1 while inducing the expression of PTEN in RCC cells. Niclosamide is further shown to synergize with Sorafenib in suppressing RCC cell proliferation and survival. In the xenograft tumor model, Niclosamide is shown to effectively inhibit tumor growth and suppress RCC cell proliferation. Conclusions: Niclosamide may be repurposed as a potent anticancer agent, which can potentiate the anticancer activity of the other agents targeting different signaling pathways in the treatment of human RCC.
显示更多 [+] 显示较少 [-]